You are not logged in.

Temozolomide in pediatric low-grade glioma

Khaw, Seong L., Coleman, Lee T., Downie, Peter A., Heath, John A. and Ashley, David 2007, Temozolomide in pediatric low-grade glioma, Pediatric blood & cancer, vol. 49, no. 6, pp. 808-811, doi: 10.1002/pbc.21270.

Attached Files
Name Description MIMEType Size Downloads

Title Temozolomide in pediatric low-grade glioma
Author(s) Khaw, Seong L.
Coleman, Lee T.
Downie, Peter A.
Heath, John A.
Ashley, David
Journal name Pediatric blood & cancer
Volume number 49
Issue number 6
Start page 808
End page 811
Total pages 4
Publisher Wiley
Place of publication London, Eng.
Publication date 2007-11
ISSN 1545-5009
Keyword(s) Adolescent
Antineoplastic Combined Chemotherapy Protocols
Astrocytoma
Brain Neoplasms
Carboplatin
Child
Child, Preschool
Dacarbazine
Disease-Free Survival
Female
Hematologic Diseases
Humans
Male
Nausea
Retrospective Studies
Spinal Cord Neoplasms
Survival Rate
Vincristine
Science & Technology
Life Sciences & Biomedicine
Oncology
Hematology
Pediatrics
low-grade glioma
temozolomide
PHASE-II TRIAL
OPTIC PATHWAY TUMORS
RECURRENT OLIGODENDROGLIOMA
VINCRISTINE CHEMOTHERAPY
CHILDREN
RADIOTHERAPY
CHILDHOOD
GLIOBLASTOMA
Summary BACKGROUND: We describe a retrospective series of children with low-grade glioma who received temozolomide. PROCEDURE: Eligible patients had had a diagnosis of low-grade glioma with or without histological confirmation. Temozolomide was administered at a dose of 200 mg/m(2) daily for 5 days, in a 4-week cycle. Therapy was stopped on completion of the targeted 12 cycles of chemotherapy or on evidence of tumor progression. RESULTS: Thirteen eligible patients were identified, eight male and five female. Median age at diagnosis was 5.5 years (range 2.6-15.0 years) and at commencement of temozolomide treatment was 9.0 years (range 3.8-15.2 years). Nine patients had a histological diagnosis of pilocytic astrocytoma. Twelve patients had received carboplatin prior to temozolomide, including three in combination with vincristine. A total of 111 cycles of therapy have been administered. Hematological toxicity and nausea were the most common adverse effects. Median time to progression was 6.7 months (range 1.5-41.8 months). Event-free survival rate at 3 years was 57%. Twelve of 13 patients remain alive at the time of report. Eleven have stable disease (SD). CONCLUSION: Temozolomide appears to be active in pediatric low-grade glioma, with the advantage of oral administration and excellent tolerability.
Language eng
DOI 10.1002/pbc.21270
Field of Research 1112 Oncology And Carcinogenesis
1114 Paediatrics And Reproductive Medicine
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2007, Wiley
Persistent URL http://hdl.handle.net/10536/DRO/DU:30070891

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 32 times in TR Web of Science
Scopus Citation Count Cited 37 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 9 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Tue, 17 Mar 2015, 11:10:02 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.